"Patients diagnosed with headache may benefit from concurrent behavioral health evaluation and treatment," researchers said.

The Food and Drug Administration has approved Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults.

About 80 million Americans fill prescriptions each year for medications to treat new instances of moderate to severe pain, ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to ...

Sonu Nigam recently suffered terrible pain at his concert in Pune. With the help of his team, he was escorted from the stage.

Singer Sonu Nigam battled severe back pain yet delivered a stellar performance at his Pune concert. In a video shared on ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.